GSK plc (LON:GSK) Insider Emma Walmsley Sells 5,473 Shares

GSK plc (LON:GSK) insider Emma Walmsley sold 5,473 shares of the business’s stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.28), for a total value of £79,303.77 ($105,499.23).

Emma Walmsley also recently made the following trade(s):

• On Monday, February 17th, Emma Walmsley sold 38,459 shares of GSK stock. The shares were sold at an average price of GBX 1,418 ($18.86), for a total value of £545,348.62 ($725,487.06).
• On Monday, February 10th, Emma Walmsley sold 120,653 shares of GSK stock. The shares were sold at an average price of GBX 1,453 ($19.33), for a total transaction of £1,753,088.09 ($2,332,164.55).

GSK Trading Up 1.0 %

Shares of GSK opened at GBX 1,377.50 ($18.33) on Friday. GSK plc has a fifty-two week low of GBX 1,242.50 ($16.53) and a fifty-two week high of GBX 1,823.50 ($24.26). The firm has a market cap of £55.90 billion, a price-to-earnings ratio of 22.25, a PEG ratio of 1.24 and a beta of 0.31. The firm has a 50 day moving average price of GBX 1,425 and a 200-day moving average price of GBX 1,398.12. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities research analysts forecast that GSK plc will post 175.980975 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on GSK shares. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Friday, March 28th. Shore Capital reissued a “buy” rating on shares of GSK in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, GSK has an average rating of “Moderate Buy” and an average price target of GBX 1,862.50 ($24.78).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.